A 32-year-old man with schizophrenia is started on haloperidol 10 mg daily. After 3 weeks, he develops severe akathisia and oculogyric crisis. His psychiatrist switches him to olanzapine 10 mg daily. Which pharmacological feature of olanzapine best explains the resolution of his extrapyramidal side effects?

Explanation

## Why Olanzapine Resolves Haloperidol-Induced Extrapyramidal Side Effects ### Pathophysiology of EPS with Typical Antipsychotics **Key Point:** Haloperidol causes EPS because it produces **sustained, high-affinity D2 blockade in the nigrostriatal pathway**, disrupting the dopamine–acetylcholine balance that maintains normal motor control. ### Mechanism of EPS Resolution with Olanzapine Olanzapine (an atypical antipsychotic) resolves EPS through two complementary mechanisms: 1. **Rapid D2 dissociation** - Olanzapine binds D2 receptors with high affinity but **rapidly dissociates** (t~1/2~ of minutes to hours) - Haloperidol shows slow dissociation (sustained blockade) - Rapid dissociation allows transient dopamine signaling, reducing motor pathway disruption 2. **Potent muscarinic M1 antagonism** - Olanzapine is a **strong M1 antagonist** (anticholinergic activity) - M1 blockade **increases striatal acetylcholine availability** (by blocking feedback inhibition) - Restored dopamine–acetylcholine balance → resolution of akathisia, dystonia, and parkinsonism ### Comparative Mechanism Diagram ```mermaid flowchart TD A[Haloperidol: Sustained D2 blockade]:::action --> B[Dopamine↓ in striatum]:::outcome B --> C[Acetylcholine unopposed]:::outcome C --> D[DA/ACh imbalance]:::urgent D --> E[EPS: akathisia, dystonia, parkinsonism]:::urgent F[Olanzapine: Rapid D2 dissociation + M1 antagonism]:::action --> G[Transient D2 blockade]:::outcome G --> H[Dopamine signaling preserved]:::outcome F --> I[M1 blockade → ACh↑]:::outcome H --> J[DA/ACh balance restored]:::outcome I --> J J --> K[EPS resolved]:::outcome ``` ### Clinical Correlate Table | Feature | Haloperidol | Olanzapine | |---------|-------------|------------| | D2 dissociation | Slow (sustained blockade) | Rapid (transient blockade) | | Muscarinic M1 activity | Minimal | Potent antagonist | | Striatal DA/ACh ratio | Severely decreased | Maintained | | EPS incidence | ~30% | ~5% | | Anticholinergic side effects | Minimal | Moderate (dry mouth, constipation) | **High-Yield:** The **M1 antagonism of atypical antipsychotics is not a bug — it is a feature** that protects against EPS by restoring dopamine–acetylcholine balance. This is why adding anticholinergic agents (benztropine, trihexyphenidyl) to typical antipsychotics reduces EPS. **Mnemonic:** **RAPID = Receptor Antagonism with Partial Inhibition and Dissociation** — atypicals use rapid D2 dissociation + muscarinic blockade to avoid EPS. **Clinical Pearl:** Patients switching from haloperidol to olanzapine often experience EPS resolution within **3–7 days**, even before steady-state olanzapine levels are reached, because rapid D2 dissociation begins immediately. [cite:KD Tripathi 8e Ch 11; Harrison 21e Ch 385]